You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Article metrics

Article menu

Download PDFPDF

XML
Research Article
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

 

Online download statistics by month:

Online download statistics by month: December 2019 to August 2025

AbstractFullPdf
Dec 2019220
Jan 202015151
Feb 2020515115
Mar 2020626217
Apr 2020636312
May 2020575718
Jun 2020818212
Jul 2020686812
Aug 2020726827
Sep 2020595913
Oct 2020737314
Nov 2020676623
Dec 2020545414
Jan 2021565612
Feb 2021474726
Mar 2021747436
Apr 2021676827
May 2021888829
Jun 2021676722
Jul 2021626219
Aug 2021737325
Sep 2021636218
Oct 2021565643
Nov 2021616131
Dec 2021767521
Jan 2022666915
Feb 2022596227
Mar 2022828538
Apr 2022646724
May 2022959823
Jun 2022818212
Jul 202258588
Aug 202250516
Sep 2022616417
Oct 2022606218
Nov 2022727431
Dec 2022596016
Jan 2023646413
Feb 2023717213
Mar 202310610819
Apr 2023676719
May 2023797939
Jun 202310510511
Jul 2023565612
Aug 2023848415
Sep 2023646611
Oct 202310010018
Nov 202316116429
Dec 2023868615
Jan 2024585813
Feb 2024747411
Mar 202412712730
Apr 2024737316
May 2024797916
Jun 2024878618
Jul 2024808031
Aug 2024666864
Sep 2024697121
Oct 2024969727
Nov 202410611030
Dec 202440541215
Jan 202511712031
Feb 202510410536
Mar 2025747426
Apr 2025969615
May 2025919120
Jun 2025666614
Jul 2025340
Aug 2025110
Total523652841370